Shares of Aravive Inc (NASDAQ:ARAV) have earned a consensus rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $26.00.
ARAV has been the subject of several research reports. Zacks Investment Research lowered shares of Aravive from a “buy” rating to a “hold” rating in a research report on Tuesday, May 12th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Aravive in a research report on Thursday, April 30th. Finally, ValuEngine lowered shares of Aravive from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 14th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in Aravive during the first quarter valued at about $83,000. Invesco Ltd. purchased a new stake in Aravive during the first quarter valued at about $96,000. Two Sigma Advisers LP lifted its holdings in Aravive by 105.9% during the first quarter. Two Sigma Advisers LP now owns 160,325 shares of the company’s stock valued at $923,000 after purchasing an additional 82,462 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Aravive by 22.3% during the first quarter. Wells Fargo & Company MN now owns 19,843 shares of the company’s stock valued at $114,000 after purchasing an additional 3,616 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Aravive by 29.1% in the first quarter. Geode Capital Management LLC now owns 87,168 shares of the company’s stock worth $502,000 after buying an additional 19,653 shares in the last quarter. 41.74% of the stock is currently owned by institutional investors and hedge funds.
Aravive (NASDAQ:ARAV) last posted its earnings results on Wednesday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.36). On average, equities analysts expect that Aravive will post -1.91 earnings per share for the current fiscal year.
Aravive Company Profile
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Further Reading: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.